ARVINAS, INC. current report, 06 August 2021

Business Context and Reporting Period

This Form 8-K Current Report was filed by Arvinas, Inc. on August 6, 2021. The filing discloses the entry into a new material definitive agreement regarding an equity distribution program and the termination of a prior agreement.

Key Financial Metrics and Transaction Details

  • New Offering Capacity: The Company entered into an Equity Distribution Agreement allowing for the sale of common stock with an aggregate offering price of up to $300,000,000.
  • Agents: Piper Sandler & Co. and Cantor Fitzgerald & Co. serve as sales agents.
  • Compensation: The Company agreed to pay commissions of up to 3.0% of the gross proceeds from sales.
  • Prior Agreement Performance: Under the terminated prior agreement (dated October 1, 2019), the Company sold 2,593,637 shares for aggregate gross proceeds of $65.6 million.
  • Financial Statements: This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for these operational financial indicators.

Material Changes Versus Prior Period

  • Agreement Termination: The Company terminated its previous Equity Distribution Agreement with Piper Sandler & Co., which had a remaining capacity of up to $100.0 million.
  • Capacity Expansion: The new agreement increases the potential offering size from the prior $100.0 million limit to $300.0 million.
  • Agent Structure: The new agreement adds Cantor Fitzgerald & Co. as a co-agent alongside Piper Sandler & Co., whereas the prior agreement was solely with Piper.

Guidance, Outlook, and Risks

  • Offering Method: Shares will be sold via "at-the-market" offerings on The Nasdaq Global Select Market or other existing trading markets.
  • Flexibility: The Company or the Agents may suspend or terminate the offering upon notice to the other party.
  • Legal Opinion: Wilmer Cutler Pickering Hale and Dorr LLP issued a legal opinion regarding the shares.
  • Outlook: The filing does not provide specific management commentary on future revenue guidance, clinical trial timelines, or operational outlook beyond the capital raising mechanism.

Important Facts for Investor Verification

  • Verify the current market price of ARVN stock to assess potential dilution from the $300 million offering capacity.
  • Confirm the Company's current cash position and burn rate to understand the necessity of this capital raise.
  • Review the attached Prospectus Supplement (filed separately) for specific terms regarding the sale of shares.
  • Monitor future 8-K filings for actual sales volumes and proceeds generated under the new agreement.